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Abstract 
Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children, and imposes 
significant morbidity and mortality in this population. The aggressive chemoradiotherapy required to 
treat high-risk NB results in survival of less than 50%, yet is associated with significant long-term adverse 
effects in survivors. Boosting efficacy and reducing morbidity are therefore key goals of treatment for 
affected children. We hypothesize that these may be achieved by developing strategies that both focus 
and limit toxic therapies to the region of the tumor. One such strategy is the use of targeted image-guided 
drug delivery (IGDD), which is growing in popularity in personalized therapy to simultaneously improve 
on-target drug deposition and assess drug pharmacodynamics in individual patients. IGDD strategies can 
utilize a variety of imaging modalities and methods of actively targeting pharmaceutical drugs, however in 
vivo imaging in combination with focused ultrasound is one of the most promising approaches already 
being deployed for clinical applications. Over the last two decades, IGDD using focused ultrasound with 
“microbubble” ultrasound contrast agents (UCAs) has been increasingly explored as a method of 
targeting a wide variety of diseases, including cancer. This technique, known as sonopermeation, 
mechanically augments vascular permeability, enabling increased penetration of drugs into target tissue. 
However, to date, methods of monitoring the vascular bioeffects of sonopermeation in vivo are lacking. 
UCAs are excellent vascular probes in contrast-enhanced ultrasound (CEUS) imaging, and are thus 
uniquely suited for monitoring the effects of sonopermeation in tumors. 
Methods: To monitor the therapeutic efficacy of sonopermeation in vivo, we developed a novel system 
using 2D and 3D quantitative contrast-enhanced ultrasound imaging (qCEUS). 3D tumor volume and 
contrast enhancement was used to evaluate changes in blood volume during sonopermeation. 2D 
qCEUS-derived time-intensity curves (TICs) were used to assess reperfusion rates following 
sonopermeation therapy. Intratumoral doxorubicin (and liposome) uptake in NB was evalauted ex vivo 
along with associated vascular changes.  
Results: In this study, we demonstrate that combining focused ultrasound therapy with UCAs can 
significantly enhance chemotherapeutic payload to NB in an orthotopic xenograft model, by improving 
delivery and tumoral uptake of long-circulating liposomal doxorubicin (L-DOX) nanoparticles. qCEUS 
imaging suggests that changes in flow rates are highly sensitive to sonopermeation and could be used to 









drug uptake during sonopermeation. Following sonopermeation treatment, vascular biomarkers show 
increased permeability due to reduced pericyte coverage and rapid onset of doxorubicin-induced 
apoptosis of NB cells but without damage to blood vessels.  
Conclusion: Our results suggest that significant L-DOX uptake can occur by increasing tumor vascular 
permeability with microbubble sonopermeation without otherwise damaging the vasculature, as 
confirmed by in vivo qCEUS imaging and ex vivo analysis. The use of qCEUS imaging to monitor 
sonopermeation efficiency and predict drug uptake could potentially provide real-time feedback to 
clinicians for determining treatment efficacy in tumors, leading to better and more efficient personalized 
therapies. Finally, we demonstrate how the IGDD strategy outlined in this study could be implemented in 
human patients using a single case study. 
Key words: Sonoporation, sonopermeabilization, sonopermeation, neuroblastoma, quantitative contrast- 
enhanced ultrasound (qCEUS), image-guided drug delivery. 
Introduction 
Neuroblastoma (NB) is the most prevalent 
extracranial solid tumor in infants and children. NB 
most often originates in the adrenal gland [1] and is 
diagnosed at a median age of 22 months. This 
malignancy is responsible for 15% of all childhood 
cancer deaths [2]. High-risk NB is currently treated 
with maximally intense chemoradiotherapy, 
immunotherapy, and autologous stem cell transplant 
[3,4]. Despite this, about half of the afflicted patient 
population will die of this disease [5]. For survivors, 
this intense therapy is associated with long-term 
toxicities [6]. For example, doxorubicin – which is a 
key component of multiagent chemotherapy for 
aggressive NB – is implicated in both acute and 
chronic adverse effects, including life-threatening 
cardiotoxicity [7]. Therefore, methods of improving 
chemotherapeutic delivery are sorely needed to 
achieve better efficacy and reduce systemic toxicity. 
One approach to this goal has been the 
development of nanomedicines to improve the 
circulation of drugs and payload into tumors. This 
strategy employs carrier vehicles with diameters 
between 10 and 200 nm to convey therapeutic drugs, 
which can either actively or passively target tumors in 
vivo. Currently, the most common method of targeting 
nanomedicines to cancers is by passive accumulation 
via the well-described Enhanced Permeability and 
Retention (EPR) effect [8]. The EPR effect is commonly 
attributed to aberrant tumor vasculature, which is 
leaky (allowing ingress) and deficient in lymphatics 
(restricting drainage), causing long-circulating 
nanomaterials (between 50 and 750 nm) to gradually 
accumulate [9–11]. This strategy was exploited in the 
first FDA-approved nanomedicine, liposomal 
doxorubicin (L-DOX) or Doxil™, which was 
developed to extend the circulating half-life of 
doxorubicin, enhancing both deposition of drug 
payloads within tumors and reducing drug 
cardiotoxicity [12]. While this approach has been 
shown to function in specific cancer types, the use of 
nanomedicines such as L-DOX has not had the 
anticipated impact of significantly extending patient 
survival [13,14].  
Furthermore, various studies have discovered 
the EPR effect to be highly dependent on the cancer 
type and stage [15]. The extent of the EPR effect has 
been demonstrated to be highly exaggerated in 
xenograft tumor models, with less reliable efficacy in 
clinical cancers [16–18]. Given this reality, novel 
strategies must be pursued to enhance the 
intratumoral accumulation of doxorubicin and other 
chemotherapeutics. More efficient delivery of 
circulating drugs could also cut down off-target 
adverse effects by reducing required systemic dosages 
for therapy [19]. In these studies, we show that 
ultrasound-based IGDD holds promise as a means of 
achieving these therapeutic goals. 
One promising method of overcoming reliance 
on the EPR effect utilizes the combination of 
ultrasound contrast agents (UCAs, also known as 
microbubbles) and focused ultrasound. Microbubbles 
are sound-sensitive gas-filled spheres (1-10 µm in 
diameter) that can mechanically disrupt cell bilayers 
or cellular gap junctions, allowing increased uptake of 
circulating drugs [20–23]. Numerous studies have 
established that volumetric oscillation of the UCA in 
an ultrasound field can promote intracellular uptake 
of drugs by a membrane-permeabilizing process 
known as “sonopermeation” (also termed 
“sonoporation” or “sonopermeabilization”) [24–26]. 
This technique has been utilized to achieve improved 
intracellular delivery of a wide variety of therapeutic 
compounds, including proteins [27], DNA [28–32], 
and nanoparticles such as liposomal doxorubicin [33, 
34].  
Despite these advances, nanoparticle delivery to 
cancer in vivo remains challenging. Physical 
co-treatments such as sonopermeation have 
progressively been adopted for applications such as 
blood-brain barrier (BBB) opening [35]; Aryal et al 





doubled DOX concentrations in rat gliomas by 
co-injecting L-DOX with microbubbles and sonicating 
with focused US [36]. Nevertheless, to date, only a few 
groups have employed sonopermeation in vivo to 
enhance L-DOX delivery to tumors beyond the brain. 
Theek et al showed that sonopermeation could 
improve intratumoral drug penetration, even in 
tumor models characterized by extensive stromal 
compartments and dense collagen networks [37]. 
Tinkov et al illustrated that sonopermeation caused 
preferential uptake of doxorubicin in tumors, and 
noted a 12-fold increase in intratumoral drug 
concentration following sonopermeation [38]. The 
majority of these studies used microscopy and tissue 
extraction procedures to quantify drug accumulation, 
quantifying tumor growth curves by physical caliper 
measurements [39]. Thus, a major obstacle to 
implementing sonopermeation therapy in clinical 
practice is that ex vivo analysis currently functions as 
the only method to quantify drug uptake and monitor 
its bioeffects. 
In the context of ultrasound-triggered 
microbubble destruction (UTMD), passive cavitation 
detection is being investigated as a technique to map 
acoustic emissions in order to calculate stable and 
inertial cavitation doses [40]. This technique assumes 
that the risk of vascular damage correlates with 
increasing cavitation doses, but it doesn’t accurately 
map the bioeffects associated with sonopermeation, 
since it focuses primarily on cavitation responses of 
the bubbles. Conversely, perfusion kinetics are 
dictated by the biology of the vasculature itself, and 
thus hold the potential to divulge the degree to which 
sonopermeation has altered vascular architecture and 
flow characteristics. We therefore set about to monitor 
sonopermeation efficacy in vivo using real-time 
perfusion imaging as feedback. Our study aimed to 
accomplish three objectives: (1) to demonstrate that 
sonopermeation can efficiently increase L-DOX 
uptake in tumor tissue (using a orthotopic 
neuroblastoma xenograft model), (2) to gauge 
whether perfusion kinetics can predict 
sonopermeation-induced efficiency of intratumoral 
drug uptake in vivo using quantitative 
contrast-enhanced ultrasound (qCEUS) imaging of 
the tumor vasculature, and (3) to explore molecular 
changes in NB in response to sonopermeation 
therapy, in order to better elucidate mechanisms of 
drug uptake.  
In the course of this study, we show that 
contrast-enhanced focused ultrasound therapy can 
effectively increase nanoparticle uptake in 
experimental neuroblastoma by ~5-fold, and that 
qCEUS imaging can function as an effective predictor 
of sonopermeation efficiency in vivo. Specifically, our 
study results indicate that reperfusion rates (flow 
rates following a short fragmentation US pulse) are 
very sensitive to immediate changes in vascular 
permeability induced by bubbles. Changes in 
reperfusion rates immediately after sonopermeation 
increased by ~2-fold when using tumor-free Matrigel 
plug models, but decreased by ~2-fold when using 
neuroblastoma tumor models. Changes in total 
perfusion volume did not fluctuate significantly in 
either Matrigel plugs or neuroblastoma xenografts 
following sonopermeation. Although overall 
perfusion did not change significantly from pre- to 
post-treatment, we show that initial tumor perfusion 
can be a critical determinant of total chemotherapeutic 
uptake. Our results indicate that liposomal 
doxorubicin can effectively be delivered using 
focused ultrasound and microbubbles without 
damaging the integrity of blood vessels comprising 
the tumoral vascular network, which is essential for 
continued chemotherapeutic delivery to tumors.  
We also demonstrate the biological effects of 
sonopermeation in neuroblastoma xenografts at 30 
min and 24 h post-treatment. We show that 
ultrasound exposure with microbubbles causes 
discontinuous pericyte coverage and distended blood 
vessels, which likely leads to increased drug 
permeability and slower blood flow observed using 
qCEUS. Apoptotic effects of doxorubicin on tumor 
cells are apparent 24 h after sonopermeation using 
TUNEL staining, while no significant change in 
apoptosis is observed with sonopermeation alone. 
Our results suggest that anti-tumoral effects are 
instigated by drug treatment rather than the 
mechanical effects of microbubbles and ultrasound. 
Lastly, a case study in which image-guided qCEUS 
imaging was used to examine the effects of bubble 
destruction in a liver tumor, using a protocol 
analogous to the methodology used in neuroblastoma 
xenografts, has also been included to demonstrate the 
clinical feasibility of this strategy. 
Together, this data serves as proof-of-principle 
that ultrasound image-guided therapy can provide a 
robust and rational approach to monitoring 
sonopermeation in vivo, with potential for predicting 
and controlling drug dosing in a clinical setting.  
Materials and Methods 
Preparation of Microbubbles 
Microbubbles were formulated using a lipid film 
composed of 14.34 mg of 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC, 790.16 MW) and 5.66 mg of 
N-(methylpolyoxyethylene oxycarbonyl)-1,2-dis-
tearoyl-sn-glycero-3-phosphoethanolamine (DSPE- 
PEG2000, 2805.97 MW) (NOF Corporation, Tokyo, 





Japan), dissolved in chloroform (Sigma-Aldrich, St. 
Louis, MO). The lipid solution was evaporated for 48 
h and then stored as a lipid film in a sealed 
scintillation vial at -20 °C. On the day of intended use, 
the 20 mg film was diluted to 2 mg/mL in a filtered 
mixture of 10% propane-1,2-diol (propylene glycol, 
76.1 FW) (v/v), 10% propane-1,2,3-triol (glycerol, 
92.09 FW) (v/v), and 10× phosphate buffer saline 
(PBS) diluted to 1× (Fisher Scientific, Waltham, MA). 
The lipid solution was heated to 65 °C on an Isotemp 
Heating Block and bath sonicated in a 1.9 L Ultrasonic 
Bath Sonicator (Fisher Scientific, Waltham, MA) until 
the lipid was completely suspended. Microbubbles 
were generated using probe micro-tip sonication 
(Branson 450 Ultrasonics Sonifier with microtip 
attachment, Emerson, St. Louis, MO) at 70% power 
under constant flushing with Decafluorobutane (PFB, 
238 MW, FluoroMed LP, Round Rock, TX) for 10 s. 
The amalgamated lipid suspension was brought 
below the glass phase temperature and washed three 
times in a 10 mL Luer tip syringe (BD, Franklin Lakes, 
NJ) at 300 relative centrifugal force (RCF) for 3 min in 
a Bucket Centrifuge Model 5804R (Eppendorf, 
Hauppauge, NY) to concentrate and collect the 
bubbles, until the infranatant appeared clear. The 
microbubbles were characterized using a Multisizer 
4e Coulter Counter (MS4, Beckman Coulter, Brea, CA) 
to determine size distribution and concentration.  
Liposome Formulation 
A mock Doxil liposome was fabricated using a 
lipid film containing 7.56 mg of DSPC, 2.69 mg of 
cholesterol, and 2.44 mg of DSPE-PEG2000. The lipid 
solution was evaporated for 48 h and then stored as a 
lipid film in a sealed scintillation vial at -20 °C. On the 
day of intended use, the 10 mg film was diluted to 8 
mg/mL with filtered pH 7.5 PBS and heated to 65 °C 
via bath sonication until the lipid became fully 
suspended. For the purpose of fluorescence 
microscopy, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo-
dicarbocyanine dye (DiD, 498.48 MW, 1 mM dilution, 
Sigma-Aldrich, St. Louis, MO) was added to the 
liposome solution at 2.1 µg per 1 mg of lipid and 
sonicated an additional 10 min.  
Matrigel Implantation 
Optimization of image-guided drug delivery 
was initially performed in highly controllable 
Matrigel tumor models. Matrigel plugs are 
well-established angiogenesis models that have been 
extensively characterized [41,42]. Matrigel plugs are 
formed by subcutaneous injection of a soluble 
basement membrane extract derived from the 
Engelbreth-Holm-Swarm tumor (Fisher Scientific, 
Atlanta, GA). Subsequent to injection, host 
endothelial cells rapidly migrate into the plug, and 
begin blood vessel formation. Blood vessel growth 
occurs relatively uniformly between plugs and 
without the complexities and type-specific 
heterogeneity that typically occur with different 
xenograft tumor models. Therefore, we reasoned 
these could function as excellent models for studying 
the effects of sonopermeation on perfusion kinetics in 
neovasculature. Prior to injection, frozen Matrigel was 
thawed overnight on ice. 12 µg human recombinant 
basic fibroblast growth factor (bFGF, Stemgent, 
Beltsville, MD) and 350 µg heparin were added to 10 
mL Matrigel to stimulate blood vessel ingrowth. 1 mL 
of Matrigel mix was loaded into chilled 1 mL BD 
syringes using chilled 16-gauge needles. After 
loading, the needle was replaced with a 27-gauge 
needle and kept on ice until animals were prepared. 
No exogenous cells (tumor or endothelial) were used 
in Matrigel studies.  
All animal experiments were approved by the 
UT Dallas or University of Chicago IACUC. Female 
CD-1 mice (Charles River, Wilmington, MA) were 
anesthetized with 2-3% isoflurane (Vedco, St. Joseph, 
MO) and restrained in the prone position. A shaved 
and disinfected region above the left kidney received 
1 mL of chilled Matrigel solution subcutaneously, 
creating a spherical plug (1 mm3). At 14 days 
post-injection, mice were imaged with MB contrast 
agents to evaluate blood perfusion and tissues 
harvested for processing. 
Orthotopic NGP Tumor Model and 
Implantation 
NGP cells are MYC-N amplified [43], and thus 
are a commonly used model for poor prognosis NB. 
They share many features of clinical NB such as 
histology, frequency, and location of metastatic 
lesions when renally implanted [44], as was done in 
nude athymic mice (Charles River, Wilmington, MA) 
to generate tumor models for this study. Mice were 
first anesthetized with inhalable isoflurane. After 
being positioned in a sterile environment, the entire 
right side of each mouse was cleaned with ethanol 
and painted with Betadine. A 3-5 mm diagonal 
incision was made with a scalpel blade in the 
direction of the ribcage atop the kidney. The 
underlying fascia was divided with scissors to expose 
the mouse’s internal organs. The kidney was 
identified and delivered from the abdominal cavity, 
using forceps and a cotton-tipped applicator. A 
27-gauge needle (of length 1.3 cm, BD Biosciences) 
fitted to a syringe containing 100 μL of cell suspension 
(1x106 NGP cells in Phosphate Buffered Saline, 
Leibniz Institute DSMZ-GmbH, Braunschweig, 
Germany) was inserted into the kidney and its 





contents injected slowly. The kidney was then 
returned to the abdominal cavity. The incision was 
closed in layers with absorbable suture, followed by 
staples to close the skin. Mice were monitored daily to 
ensure complete recovery, and tumors were allowed 
to grow for 5-6 weeks (1-2 g weight) before ultrasound 
experiments were commenced.  
3D Volume and Perfusion Imaging 
3D imaging was performed by mounting a linear 
15L8 transducer, equipped with the Acuson Sequoia 
512 ultrasonography system (Siemens Medical 
Solutions, Erlangen, Germany), on a stepper motor, 
and sweeping it across the length of the tumor in 0.2 
mm increments. Data was collected and subsequently 
analyzed using custom LabVIEW software. The 
resulting series of 2D section scans was combined in 
ImageJ to capture volumetric measurements (B-mode) 
and to map the vasculature in and around the tumor 
(CPS mode). Non-linear contrast images were 
acquired following a bolus injection of 5x107 MBs in a 
total volume of 100 µL, administered via tail vein 
catheterization.  
Perfusion-Guided Monitoring of Drug Uptake 
in Matrigel Plugs  
Mice bearing Matrigel plugs were 3D imaged 
prior to sonopermeation to assess the initial level of 
perfusion; Matrigel plugs were utilized to mimic 
tumors as they are a good model for angiogenesis. A 
high dose of microbubbles (1x109 total MBs) was 
combined either with 25 mg/kg L-DOX (Doxoves©, 
FormuMax, Sunnyvale, CA) or FITC-Dextran (2 kDa, 
5 mg/mL in PBS) and systemically introduced via tail 
vein injection. Subcutaneous tumor-free Matrigel 
plugs were sonopermeated with a handheld 
therapeutic ultrasound machine (SoundCare Plus, 
Austin, TX) at 0-3 W/cm2 (1 MHz, 10% duty cycle, 
alternating 5 seconds on and 5 seconds off) for 10 min. 
30 min post-sonopermeation, the tumors were again 
3D imaged to evaluate changes in the vasculature. 
Finally, Matrigel, contralateral kidney, liver, and heart 
tissue were excised 24 h after sonopermeation and ex 
vivo analysis was performed (Figure 1). 
Sonopermeation In vivo Using Focused 
Ultrasound Application 
A custom lens and cone system was developed 
to elevate pressure in the focal zone (~ 2 MPa peak 
negative pressure, Supplementary Figure 1) and was 
affixed to the therapeutic ultrasound probe. A 
commercial infusion pump (Kent Scientific, 
Torrington, CT) was coupled to a custom 3D printed 
rotating syringe platform (similar to Kaya et al [45]), 
designed to evenly disperse the microbubbles in 
solution, ensuring that sustained infusions occurred 
at a fixed concentration throughout the duration of 
microbubble administration (Figure 2A). Pre- and 
post-sonopermeation perfusion kinetics were 
obtained in a single 10 min infusion: 1x109 
microbubbles were combined with 100 µL of DiD 
liposomes and brought up to a total volume of 500 µL 
with sterile saline. Microbubbles flowed into the 
tumor space at a constant rate of 50 µL/min and were 
allowed to reach steady-state over a period of 5 min, 
after which a flash-destruction pulse (MI = 1.9) was 
applied to clear all bubbles from the imaging plane. 
Microbubbles were then given 30 s to re-circulate, 
following which tumors were sonopermeated (3 
W/cm2) on/off five times for 5 s each. This procedure 
was repeated for four cycles, interspersed by 30 s gaps 
to permit replenishment. At the 10.5 min mark, the 
tumor was hit with a final flash-destruction pulse 
(Figure 2B).  
 
 
Figure 1. Cartoon depiction of workflow for unfocused ultrasound experiments. Mice bearing tumor-free Matrigel plugs were imaged (15 MHz) in 2D and 3D prior to 
sonopermeation to establish a baseline of tumor perfusion using a bolus of 5x107 MBs. Next, microbubbles and drug were systemically introduced via tail vein injection and 
subcutaneous tumors were sonopermeated with a handheld therapeutic ultrasound transducer (1 MHz) using a high concentration of MBs (1x109 MBs in 500 µL). 30 min 
post-sonopermeation, tumor-free Matrigel plugs were imaged again to assess changes in the vasculature. Finally, tissue was excised 24 h after sonopermeation and ex vivo analysis 
was performed to quantify FITC-Dextran uptake. 






Figure 2. Perfusion-guided sonopermeation of neuroblastoma tumor models using qCEUS imaging techniques to monitor vascular changes. (A) A rotating syringe pump was 
used to administer constant infusions over long periods of time during sonopermeation experiments. (B) Screen captures from the clinical ultrasound scanner illustrate non-linear 
2D imaging of a neuroblastoma tumor sonopermeated using 1x109 MBs. The selection of appropriate ROIs encompassing the sonopermeated focal zone (solid white line) and a 
designated control region (dashed white line) at the periphery of the tumor has been indicated. The series of ultrasound images show contrast enhancement before 
sonopermeation, followed by focused ultrasound triggered microbubble destruction in vivo during four sonopermeation treatment cycles, culminating in MB recovery within the 
tumor space post-sonopermeation; the accompanying time-intensity curves (TICs) – corresponding to the “treated” and “untreated” ROIs – have been split into three matching 
stages. (C) MB reperfusion after the initial (FD-1 = 300 s) and final (FD-2 = 630 s) flash-destruction pulses were fitted to an exponential model and the resultant curves were 
compared to assess sonopermeation-mediated changes in perfusion kinetics. 
 
As described by Wei et al [46], microbubble 
reperfusion following flash-destruction is governed 
by the exponential equation: 
y = A (1 – e-βt)  
Perfusion recovery curves generated from CPS 
data were fit to this form in the LabVIEW software 
and plotted on the same set of axes (Figure 2C). 
Measures of the relative blood volume (RBV = A) and 
the rate of reperfusion (RR = β) were extracted and 
compared pre-treatment and post-treatment in the 
sonopermeated region and an area outside the tumor 
(designated as the internal “control region”) for each 
mouse. 
Tumor and Matrigel Excision 
Mice were sacrificed 24 h post-sonopermeation 
by exsanguination to remove drug remaining in 
circulation. Prior to exsanguination, mice were 
anesthetized using 5% isoflurane. After confirming 
depth of anesthesia by toe pinch, animals were 
exsanguinated by intracardiac perfusion of 1% 
paraformaldehyde (for IHC of mice sonopermeated 
without drug) or cold saline (for drug quantification). 
This procedure was performed by inserting a syringe 
with 20 mL of solution into the left ventricle and 
cutting the right atrium prior to flushing out the 
mouse’s circulatory system. All Matrigel 
plugs/tumors were surgically excised for ex vivo 
processing immediately after perfusion.  
FITC Dextran Quantification in Matrigel Plugs 
Drug uptake in Matrigel plugs was evaluated 
using a procedure similar to a previously reported 
study by Prewett et al [47]. Matrigel plugs were 
removed and transferred to tubes containing 0.5 mL 
of Dispase reagent (Becton Dickinson). Plugs were 
incubated for 1 h at 37 °C and then stored overnight at 
4 °C. The plugs were then tip sonicated using a 
microtip sonicator (Branson) at 30% power until a 
homogenous slurry was obtained. Sterile saline was 
added to the tubes, which were then vortexed and 
centrifuged at 2000 rpm for 5 min. The supernatant 
was separated and the accumulated FITC-Dextran 
was quantified by measuring the fluorescent 
properties of the 2 kDa FITC (488/515 nm ex/em) on 
a fluorescent microplate reader (Synergy H1 Biotek, 
Boston, MA). A standard curve of known 
FITC-Dextran concentrations was used to determine 
total uptake in the Matrigel plugs after normalizing to 
plug weight. 
Doxorubicin Quantification in Matrigel Plugs 
and NGP Tumors 
Doxorubicin quantification used a similar 
approach adopting a combination of two 
methodologies by Bing et al [48] and Head et al [49]. 
Matrigel plugs or tumors were excised, weighed, and 
snap frozen. Sections of tissue were weighed 
(typically 50-100 mg) in 1.5 mL centrifuge tubes with a 





cell lysis buffer (consisting of 0.25 M sucrose, 5 mM 
Tris-HCl, 1 mM MgSO4, 1 mM CaCl2 pH 7.6) and 100 
µL ceramic beads (MO BIO Laboratories, Carlsbad, 
CA). The tubes were placed in a vial mixer 
(Bristol-Meyers Squibb, New York, NY) for 45 s to 
homogenize the tissue. In order to establish standards 
of known doxorubicin measurements in homogenates 
of Matrigel plugs and tumors, untreated tissue was 
mixed with 2 µL of 10 mg/mL doxorubicin (Sigma 
Aldrich) stock dissolved in DMSO and homogenized 
as described above. Spiked homogenates were then 
serially diluted with extraction buffer. The readings of 
untreated plugs or tumor samples without 
doxorubicin were considered zero. The untreated 
samples with known concentrations of doxorubicin 
were used in every plate, in order to accurately and 
consistently quantify doxorubicin accumulation in 
treated tissue. Untreated and treated homogenized 
samples (200 µL) were placed in 1.5 mL 
microcentrifuge tubes, with acidified isopropanol 
solution: 100 µL of 10% (v/v) Triton X-100 (Sigma 
Aldrich), 200 µL of water, and 1 mL of acidified 
isopropanol (0.75 N HCl, Sigma Aldrich). Samples 
were stored overnight at -20 ºC to extract the 
doxorubicin. The next day, the microcentrifuge tubes 
were warmed to room temperature, vial mixed for 45 
s, centrifuged at 2,000 g for 15 min in a mini vortexer, 
and stored at -80 ºC until analysis. The standard curve 
generated by spiking tissue with known quantities of 
doxorubicin was run side by side with experimental 
samples to quantify uptake per gram of tumor or 
Matrigel. Doxorubicin was also quantified in heart, 
liver, and contralateral kidney tissue using the same 
method. 
Fluorescent Drug Uptake in NGP Tissue 
Sections 
For NGP tumors, whole tissue sections were 
used to evaluate intratumoral accumulation of 
doxorubicin and DiD tracer liposomes to assess 
spatial distribution within the tumor. Tumors were 
embedded in Tissue-Tek® optimum cutting 
temperature (O.C.T.) compound (Electron 
Microscopy Services) over dry ice until frozen, then 
stored at -80 ºC until cryosectioned. 5 µm thick 
cryosections were visualized without mounting 
media on a confocal microscope (Marianas or SP2, 
Zeiss).  
Histology and Immunohistochemistry 
Some tumors and organs were fixed in 4% 
paraformaldehyde overnight, dehydrated in 70% 
ethanol and paraffin embedded. 5 µm sections were 
used to stain for the apoptosis marker terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL, ApopTag, Millipore, following the 
manufacturer’s instructions), the selective pericyte 
marker alpha-smooth muscle actin (αSMA) [47] 
(LabVision Actin, ThermoFisher Scientific), the 
endothelial markers Endomucin (Santa Cruz 
Biotechnology), IsolectinB4-AlexaFluor488 
(ThermoFisher Scientific), and hematoxylin and eosin. 
Whole H&Es, αSMA, Endomucin, and TUNEL tissues 
were scanned in a CRi Pannoramic Midi 20x Whole 
Slide Scanner (3DHistech). Data and images were 
analyzed using Pannoramic Viewer software 
(3DHistech). DOX and DiD were quantified on fresh 
frozen tumors stored in OCT and then cut into 5 µm 
sections, using a Marianas Confocal Microscope 
(Zeiss) at 561 nm laser (L-DOX) and 640 nm laser 
(DiD) wavelengths. At least eight images at a 40x 
magnification of three tumors per group were taken at 
random by focusing on the DAPI channel. 
Quantification was performed in ImageJ, using the 
mean grey area of 16-bit images, normalized by total 
DAPI area to account for variations in intratumoral 
structures, such as a large blood vessel without tumor 
cells. Figures were then processed in Adobe Illustrator 
cc 2018 (Adobe). In order to measure vascular caliber 
(blood vessel diameter), we used tumor sections 
stained against a marker of the endothelium, the 
innermost layer of cells in blood vessels, known as 
Endomucin. NGP tumors immunostained against 
Endomucin were scanned, and images analyzed using 
the Pannoramic Viewer software (3DHISTECH). 
Taking this endothelial marker as an indicator of the 
vascular wall, we defined the vascular caliber as the 
longest axis spanning the inside of Endomucin 
stained endothelial cells, using the “Create Distance 
Measurement Annotation” on Pannoramic Viewer 
software. One hundred measurements of vessel 
caliber were created from each tumor section in 
randomized locations within each tumor, three 
tumors were analyzed per group, and statistical 
analysis performed in Prism (GraphPad) using a 
Wilcoxon Signed Rank Test (Supplementary Figure 5). 
Lectin- and αSMA-positive cells were quantified from 
fluorescent images taken at 10x magnification on an 
Axioscop2 (Zeiss), and using the threshold tool in 
ImageJ. Statistical analysis was performed with 
Student’s T-test in Excel (Microsoft). Four pictures per 
tumor section for at least three sections were taken 
from fresh frozen samples, excluding kidney areas 
and non-viable tumor areas.  
Sonopermeation in Human Patients 
Human imaging data was collected as part of an 
ongoing clinical trial using sonopermeation for 
sensitizing hepatocellular carcinoma to 
radioembolization therapy (NCT #03199274). This 





study is approved by the Food and Drug 
Administration (IND #126,768) and the Institutional 
Review Board of Thomas Jefferson University. All 
patients provided informed consent prior to 
participation. Imaging was performed using an S3000 
scanner with a 6C1 probe and flash-replenishment 
and non-linear imaging packages (Siemens 
Healthineers, Mountain View, CA) by a sonographer 
possessing over ten years of experience. 
For contrast agent infusions, 5 mL of activated 
Optison (GE Healthcare) was suspended in 50 mL of 
saline and infused through an 18- to 20-gauge 
angiocatheter placed in a peripheral arm vein at a rate 
of 120 mL/h. The tumor midline was first imaged 
using Cadence Pulse Sequencing (MI = 0.06) for at 
least 45 s until complete enhancement of the tumor 
and adjacent liver was observed. Following complete 
enhancement, the patient was asked to temporarily 
halt respiration. Sonopermeation was performed 
using a 4 s destructive pulse from the imaging 
transducer (MI = 1.13 at 1.5 MHz, transmitting 2.3 µs 
pulses at a pulse repetition frequency of 
approximately 100 Hz), which is applied to all 
microbubbles in the field of view. Following 
sonopermeation, Optison reperfusion was imaged at 
the tumor midline for at least 10 s. This 
flash-replenishment sequence was repeated for at 
least 5 cycles at the tumor midline after which full 
intratumoral microbubble destruction was obtained 
by manually sweeping through the tumor during the 
4 s destructive sequences for the remainder of the 
infusion. Following sonopermeation, patients were 
monitored for 30 min and data extracted in DICOM 
format for off-line processing. 
Results 
Sonopermeation Using Unfocused Ultrasound 
Does Not Increase Doxorubicin Uptake in 
Matrigel Plugs 
Image-guided studies were performed by 
delivering 2 kDa FITC-Dextran molecules to 
tumor-free Matrigel plugs to test whether an 
(unfocused) commercial therapeutic ultrasound 
system can improve small molecule uptake. We 
applied 0 to 3 W/cm2 ultrasound intensities (which 
corresponded to 0-0.6 MPa PnP, Supplementary 
Figure 1). In these studies, 2D and 3D contrast 
enhanced ultrasound (CEUS) imaging was performed 
immediately before and 30 min after sonopermeation 
therapy to assess changes in overall perfusion and 
perfusion kinetics (Figure 3A-B). We did not detect 
significant changes in perfusion volume in the 
Matrigel plugs using the unfocused system (Figure 
3A). Conversely, there was a statistically significant 
increase in the rate of reperfusion after unfocused 
sonopermeation at 2 and 3 W/cm2 (Figure 3B, red vs. 
green line). 
Next, we further characterized the effects of 
unfocused ultrasound on perfusion and drug uptake 
using Matrigel plugs. 3D contrast enhancement in the 
Matrigel plugs did not show significant changes in the 
relative blood volume (RBV) following 
sonopermeation therapy at any intensity level (Figure 
4A). However, reperfusion rates measured using 
destruction-replenishment imaging showed a 
significant increase in reperfusion velocity with 
increasing ultrasound power (Figure 4B). While there 
is a linear increase in the rate of reperfusion with 
increasing ultrasound pressure, only ultrasound 
intensities of 2 W/cm2 and 3 W/cm2 had statistical 
increases in reperfusion rates above baseline (Figure 
4B, 0.03 and 0.04 s-1 respectively, p<0.05). 
Interestingly, the increase in reperfusion rate 
correlated with small-molecule FITC-Dextran uptake, 
 
Figure 3. (A) Examples of 3D reconstructions of Matrigel plugs generated from interpolating a series 2D non-linear contrast images taken pre- and post-unfocused 
sonopermeation reveal no overall changes in relative blood volume or level of perfusion. (B) Examples of 2D flash-destruction imaging performed before (green) and after (red) 
unfocused sonopermeation show an increase (p<0.05) in the rate of microbubble reperfusion in Matrigel plug models. * Indicates statistical significance in the difference between 
pre- and post-sonopermeation rates as compared to untreated Matrigel plugs.  





which showed recovery of 24.5 and 33.3 µg 
FITC-Dextran per gram of Matrigel tissue at 2 W/cm2 
and 3 W/cm2 respectively (Figure 4C, p<0.05).  
After demonstrating increased FITC-Dextran 
delivery to Matrigel plugs, the methodology was 
repeated using liposomal doxorubicin (L-DOX). 
Despite increased FITC-Dextran uptake, there were 
no significant changes in levels of doxorubicin in 
excised Matrigel plugs following the same unfocused 
sonopermeation experiments (Figure 4D). We 
rationalized that this is likely due to the size of the 
L-DOX molecules (~80 nm), which would not 
extravasate as effectively as free drug in circulation. In 
the next section, we detail our approach for 
improving sonopermeation efficiency of liposomes 
using focused ultrasound. In all subsequent 
experiments, only uptake of large molecule L-DOX or 
liposomes was investigated. 
Sonopermeation Using Focused Ultrasound 
Increases Liposome and Doxorubicin Uptake 
in Matrigel Plugs 
In order to achieve higher levels of ultrasound 
application that would facilitate larger molecule 
uptake in tumors, we utilized a custom focusing lens 
attached to the therapeutic ultrasound system to 
generate pressures up to 2.35 MPa (Supplementary 
Figure 1) within the tumor space. We then tested 
whether focused ultrasound could increase larger 
particle (80 nm liposomes) uptake in Matrigel plugs. 
In order to facilitate ex vivo detection, the liposomes 
were labeled by incorporating DiD in the bilayer. 
Focused ultrasound was applied at a maximal 
pressure of 2 MPa using either 108 or 109 total MBs 
together with liposomes diluted in PBS. Similar to 
unfocused ultrasound (Figure 4A), total perfusion in 
the Matrigel plugs remained unchanged before and 
after sonopermeation (Figure 5A), but reperfusion 
rates increased significantly in the focal region where 
ultrasound was applied (Figure 5B). Liposomal 
uptake was detected in Matrigel plug cross sections 
by DiD fluorescence (Figure 5C, purple) and greater 
accumulation was qualitatively observed in the 
sonopermeated tumors as compared to the untreated 
negative control tumors (Figure 5C, middle and right 
panel vs. left panel). 
 
Figure 4. Effect of unfocused sonopermeation on tumor perfusion and drug uptake. Mice assigned to the untreated group received neither microbubbles nor 
FITC-Dextran/DOX nor ultrasound, whereas the 0 W/cm2 group received microbubbles co-injected with FITC-Dextran/DOX without ultrasound. (A) Percent change in the 
relative blood volume before and 30 min post-sonopermeation from 3D qCEUS. (B) Change in reperfusion rates before and after sonopermeation. (C) Small molecule (2 kDa) 
FITC-Dextran uptake in Matrigel plugs 24 h post-sonopermeation. (D) Doxorubicin uptake delivered using liposomal L-DOX 24 h post-sonopermeation. Ultrasound intensities 
from 0-3 W/cm2 correspond to 0-0.6 MPa PnP. N = 4-5 mice per group. * Indicates p<0.05 compared to the untreated group. 
 







Figure 5. Evaluation of focused ultrasound treatment on qCEUS parameters and DiD Liposome uptake in Matrigel plugs. (A) Changes in RBV from baseline (before 
sonopermeation) using two different concentrations of MBs co-injected with DiD labeled liposomes. (B) Change in reperfusion rate after sonopermeation using the same tumors. 
Values were calculated by selecting an ROI in the sonopermeated focal zone and normalizing against non-sonopermeated control ROIs outside of the tumor area, as described 
in Figure 2. A paired Student’s T-test was performed with N = 3 mice per group. * Indicates p<0.05 and ** indicates p<0.01 and reflect that these groups are significantly different 
than the baseline value. (C) Effect of MB concentration on nanoparticle accumulation. Sections of sonopermeated and non-sonopermeated Matrigel plugs were visualized on a 
whole slide scanner (Olympus VS120 Virtual Slide Microscope). 
 
Furthermore, ex vivo analysis of Matrigel plugs 
showed increased levels of RBC extravasation at 
elevated pressures of up to 2 MPa using focused 
ultrasound, potentially indicative of egress of 4-7 μm 
diameter particles (murine erythrocytes are 4-7 μm; 
Supplementary Figure 3, arrows).  
Next, we asked whether sonopermeation with 
focused ultrasound would increase L-DOX uptake in 
Matrigel plugs. When sonopermeated and 
non-sonopermeated mice were compared, a 5-fold 
increase in L-DOX accumulation was observed in 
Matrigel plugs accompanied by no statistically 
significant change in any of the other organs analyzed 
(Figure 6, p<0.05). Histological analysis confirmed 
this tissue extraction data, wherein greater liposomal 
uptake was noted in Matrigel tumors alone (Figure 
5C, data for heart, liver and kidney not shown). While 
only one L-DOX concentration was tested in this 
study, future studies that examine a lower range of 
concentrations are warranted to demonstrate that 
lower dosages can achieve an equivalent therapeutic 
response to standard L-DOX treatments. 
Initial Degree of Vascularity Influences the 
Extent to Which Sonopermeation Enhances 
Doxorubicin Uptake 
Since no change in relative blood volume was 
distinguishable pre- and post-sonopermeation 
(Figures 3A & 5A), we addressed the question of 
whether perfusion volume does, in fact, affect 
sonopermeation efficiency. Given that the number 
and size of blood vessels will increase over time in a 





Matrigel plug, we evaluated whether the number of 
days post-implantation, and thus vascularization 
levels, affect DOX uptake. We found that vascularity 
alone does not facilitate DOX uptake (Figure 7A, 
white circles). However, when sonopermeation is 
combined with greater perfusion volume, there is a 
linear increase in L-DOX uptake (Figure 7A, black 
diamonds), implying that the level of tumor perfusion 
may serve as a good predictor of drug accumulation. 
Increases in vascularity were confirmed in 
sonopermeated mice with qCEUS imaging (Figure 7B) 
by using the relative blood volume (RBV, measured in 
arbitrary pixel units) and normalizing to tumor 
volume (TV, mm3). Example images of perfusion 
within tumor-free Matrigel plugs at varying time 
points post-implantation are shown in Figure 7C. 
Matrigel plug sizes tend to shrink over time as they 
are reabsorbed in the body while blood vessel growth 
continues to increase with time, likely leading to more 
efficient doxorubicin uptake per unit volume. 
 
 
Figure 6. Focused ultrasound increases drug uptake in Matrigel plugs. A 5-fold 
increase in L-DOX accumulation was achieved in Matrigel plugs sonopermeated with 
a high dosage of microbubbles (109 MBs in 500 µL) as compared to their 
non-sonopermeated counterparts, accompanied by no statistically significant 
difference in other organs, suggesting that sonopermeation drove more L-DOX 
selectively into the tumor without simultaneously increasing uptake in the heart, all 




Figure 7. Effect of Matrigel age and perfusion on doxorubicin uptake. (A) Sonopermeation efficiency increases with Matrigel plug maturity (black diamonds). No effect of Matrigel 
age on doxorubicin uptake is observed without sonopermeation (white circles). (B) Normalized relative blood volume (RBV) measurements from qCEUS imaging of Matrigel 
plugs show a similar increasing trend in doxorubicin uptake with increased perfusion. (C) Examples of 3D qCEUS measurements of tumor volume (TV) and perfusion (RBV) from 
four sonopermeated Matrigel plugs. Matrigel plugs are reabsorbed over time causing a decrease in TV while RBV increases, thus enhancing the effectiveness of sonopermeation. 






Figure 8. Effect of sonopermeation alone (no L-DOX) on qCEUS parameters and NGP tumoral vasculature 30 min post-treatment. (A) Change in RBV after sonopermeation 
within the sonopermeated tumor compared to unsonopermeated control region outside the tumor (see Figure 2 for ROI selection). (B) Change in RR after sonopermeation 
using the same ROIs. (C-G) Ex vivo analysis of NGP tumors harvested 30 min after sonopermeation alone (right column) or following no treatment (Untreated Control, left 
column). (C) Hematoxylin (blue) and eosin (pink-red) (top and middle rows) with remaining kidney (KD, light pink) highlighted by the dotted black line (top row) revealed no 
change in cell death as a result of sonopermeation (homogeneous blue staining). (D) 20x magnification (middle row) of an area away from normal kidney (yellow dotted square 
in top row) shows increased blood vessel diameter (black arrows) in the treated tumors compared to untreated controls. (E) Sonopermeation led to discontinuous pericyte 
coverage (black arrowheads) illustrated by interrupted alpha-smooth muscle actin immunostain (αSMA, third row). (F) TUNEL staining (red, white arrows) was used to detect 
cell death, which was minimally observed in untreated or sonopermeation alone mice. (G) Sonopermeation alone increases blood vessel dilation. Lumens (“L”) were measured 
using Pannoramic Viewer; the longest distance between Endomucin immunostained cells was measured, and over 100 measurements of randomized locations per tissue were 
analyzed (see Supplementary Figure 5). N = 3 mice per group.  
 
Sonopermeation Increases Vascular 
Permeability in Neuroblastoma 
Next, we turned our focus from Matrigel model 
tumors to orthotopic human NB xenografts. Similar to 
the Matrigel model, quantification of changes in 
relative blood volume divulged no statistically 
significant change in the level of perfusion between 
the non-sonopermeated and sonopermeated regions 
in xenografts (Figure 8A). However, a significant 
decrease (79±23%, p<0.01) in reperfusion rate was 
observed in the sonopermeated region compared to 
the untreated control region (Figure 8B). In order to 
further characterize the effects of sonopermeation 
alone, we analyzed tumor histology 30 min after 
treatment. Hematoxylin and eosin (H&E) revealed 
sonopermeated tumor overall histology and 
architecture were comparable to that of untreated 
controls (Figure 8C). The lighter, pink areas 
demarcate remnant kidney tissue (Figure 8C, first row 
“KD”), unaltered by sonopermeation, and blue 
staining overall indicates no loss of tumor viability or 





architectural changes (Figure 8C). Upon higher 
magnification, we found that sonopermeation did 
induce vascular dilation versus untreated controls 
(Figure 8D, black arrows). In order to confirm 
whether sonopermeation affected the vascular lumen, 
we immunostained tumors against the endothelial 
marker Endomucin. We then measured the longest 
axis between Endomucin-stained endothelial cells on 
opposing vessel walls, and validated that 
sonopermeation significantly increased vascular 
dilation (Figure 8G; median diameter of 15.9 µM for 
controls compared to 21.5 µM for sonopermeation, 
RankSum 653 in controls vs. 3003 in sonopermeation, 
p<0.0001). Pericytes contribute to capillary diameter 
and vascular permeability through their direct contact 
with endothelial cells; we interrogated the effect of 
sonopermeation on pericytes using the marker αSMA 
(reviewed by Bergers and Song [50]), used to identify 
mature pericytes in experimental neuroblastoma [51]. 
Immunostaining of sonopermeated tumors revealed 
discontinuous pericyte coverage of endothelial cells, 
consistent with increased vascular dilation and 
permeability (Figure 8E, black arrowheads). In order 
to determine whether changes in pericyte 
morphology were due to pericyte death, we analyzed 
the apoptosis marker TUNEL. TUNEL staining 
revealed no change in pericyte apoptosis in the 
sonopermeated tumors (Figure 8F, white arrows), or 
in the number of TUNEL positive αSMA cells (data 
not shown). Finally, we observed an increase in 
extravasated red blood cells adjacent to discontinuous 
pericytes as a result of sonopermeation (Figure 8E, 
8G). Together, this data suggests that sonopermeation 
itself (at the prescribed settings in this study) can 
increase vascular permeability in NGP tumors 
without damaging the vasculature. 
Sonopermeation Increases Doxorubicin 
Uptake in Orthotopic NB Xenograft Tumors 
and Increases Tumor Apoptosis 
NGP tumors receiving L-DOX and DiD 
liposomes without sonopermeation had 231±33% 
increase in L-DOX fluorescent intensity compared to 
untreated ones (Figure 9B, p<0.05). DiD signal, 
however, was barely detectable in this group, only 
127±96% of the untreated control (Figure 9C, p=ns). In 
contrast, sonopermeated tumors had 476±89% L-DOX 
compared to untreated controls and 204±38% more 
L-DOX than non-sonopermeated mice (Figure 9B, 
p<0.01); we found L-DOX to accumulate in the nuclei 
of tumor cells that had undergone sonopermeation 
(Figure 9A, top right panel, green). In parallel with 
this finding, sonopermeated tumor DiD fluorescence 
was 514±232% of untreated controls (Figure 9C, 
p=0.04) and 404±183% of non-sonopermeated mice 
(Figure 9C, p=0.056); mice treated with L-DOX and 
DiD liposomes without sonopermeation had no 
difference in DiD compared to untreated controls 
(Figure 9C, p=ns). This data suggests increased 
vascular permeability as a result of sonopermeation. 
Next, we quantified the vascular lumen 24 h 
post-sonopermeation by measuring the intervening 
length between cells lining the vasculature on either 
side of the vessel, using the Endomucin marker 
(Figure 9A, bottom row, brown color). Indeed, the 
vascular caliber was significantly larger in 
sonopermeated tumors than in untreated controls 
(median diameter of 15.9 µM for controls versus 29.8 
µM for sonopermeation; Rank Sum 653 vs. 4072 
respectively, p<0.0001), demonstrating that the 
vascular dilation observed 30 min 
post-sonopermeation (Figure 8G) not only persisted 
but increased 24 h later (p<0.01). Meanwhile, lumens 
of tumors receiving L-DOX without sonopermeation 
were not different from untreated controls (Figure 9A, 
bottom row, middle panel).  
Next, we analyzed the effects of enhanced, 
sonopermeation-induced L-DOX delivery to tumors 
at the cellular level. Histological analysis revealed 
large clusters of TUNEL positive tumor cells in 
sonopermeated tumors (Figure 9A, middle row, white 
dots, yellow arrows). Although L-DOX alone 
increased the number of apoptotic tumor cells 
compared to untreated controls, the pattern of 
apoptotic cells remains scattered throughout the 
tissue, suggesting that many tumor cells escaped 
L-DOX treatment in the absence of sonopermeation. 
Sonopermeation, on the other hand, revealed large 
areas of tumor cell death owing to the effects of DOX 
after a single treatment, as is evident in this example 
(Figure 9A, middle right panel, yellow arrows). In 
sum, our data suggests that sonopermeation increases 
tumoral DOX uptake by increasing vascular 
permeability.  
Sonopermeation in Clinical Testing 
Here, we present the results from a single patient 
sonopermeation experiment (Figure 10). Similar to 
NGP xenograft studies which show slower 
reperfusion following 4 cycles of sonopermeation, 
qCEUS also shows a slight decrease in relative blood 
volume (RBV) following sonopermeation (Figure 
10C); however the UCA replenishment times in this 
study were much shorter than what was used for 
NGP xenograft studies, thus full reperfusion may not 
be observed. Although the procedures and results 
between human and animal testing were similar, 
there are several key differences between the 
experiments noted in the discussion section. 







Figure 9. Evaluating drug uptake and vasculature changes in NGP tumors 24 h after sonopermeation. (A) Ex vivo evaluation of NGP tumors using histology and immunostaining 
to evaluate levels of doxorubicin and liposomal DiD uptake, cell death (TUNEL), lectin, αSMA, and Endomucin (lumen). Untreated tumors (left column) were compared with 
tumors given L-DOX and DiD liposomes only (no sonopermeation, middle column), and sonopermeated tumors (right column). Low magnification of the apoptosis marker 
TUNEL reveals that sonopermeation with L-DOX led to large clusters of apoptotic tumor cells at 24 h (second row, white dots, yellow arrows) although no observable changes 
in blood vessel (lectin) or pericyte coverage (αSMA) were observed (third row). Sonopermeation caused enlargement of vascular lumens (marked L) in the presence of L-DOX: 
lumens were measured using Pannoramic Viewer, the longest distance separating Endomucin immunostained cells was measured, and over 100 measurements of randomized 
locations per tissue were analyzed (see Supplementary Figure 5). (B) Quantification of doxorubicin in NGP tumors calculated by average fluorescent intensity within the tumors. 
Image intensities are ~2 and 5-fold higher for L-DOX/DiD only and sonopermeated tumors with L-DOX/DiD respectively. Untreated controls show a small level of background 
signal due to tissue autofluorescence. (C) Comparison of liposome uptake in NGP tumors using average DiD fluorescent intensity. Infusion of L-DOX without sonopermeation 
did not alter DiD uptake in tumors compared to the untreated controls. Sonopermeation increased DiD presence in the tumors approximately 5-fold. (D) Quantification from 




The clinical impact of contrast-enhanced 
ultrasound imaging is growing rapidly, yet the 
application of qCEUS imaging in drug therapies 
remains limited. In this study, we combine qCEUS 
imaging with a technique known as 
“sonopermeation” (also called “sonoporation” or 
“sonopermeabilization”) to facilitate drug uptake in 
an experimental model of neuroblastoma and monitor 
tumor response to sonopermeation therapy in vivo. 
Sonopermeation using UCAs can effectively increase 
vascular permeability, thus eliminating dependence 
on the endogenous tumor vasculature. However, 
methods of monitoring and controlling vascular 
permeability in vivo are lacking. The overall goal of 
this study was to demonstrate that sonopermeation is 
a rational approach to improving the efficacy of 
liposomal doxorubicin therapy in neuroblastoma and 
that contrast-enhanced imaging can be used to 
monitor the effects of sonopermeation and accurately 
assess liposomal drug uptake in vivo. Over the course 
of this study, we developed a unique methodology 
with clinical potential for simultaneously monitoring 
and treating neuroblastoma (and other solid tumors) 
using sonopermeation therapy, capitalizing on 2D 
and 3D qCEUS imaging. 
 






Figure 10. Sonopermeation in a clinical setting. The above images constitute an example of how image-guided sonopermeation can be accomplished in patients using a single 
continuous infusion of ultrasound contrast agents. (A) Summary of methodology for performing imaging and flash-destruction cycles followed by full destruction of contrast 
agents. (B) Representative images of contrast agent infusion, contrast agent destruction, and reflow in hepatocellular carcinoma (outlined in white). (C) Mean pixel intensities 
immediately following the first (green) and last (red) flash destruction pulse. 
 
Monitoring Sonopermeation and Evaluating 
Drug Uptake in Matrigel Plug Models 
Our initial experiments were performed in 
Matrigel plug models in order to evaluate small 
molecule drug uptake (2 kDa) and liposomal 
doxorubicin uptake using relatively low-ultrasound 
intensities (<0.6 MPa). Our results demonstrated that 
sonopermeation did in fact promote small molecule 
delivery using 2 kDa FITC-Dextrans without 
noticeable changes in total perfusion (measured by 3D 
qCEUS imaging). Interestingly, we observed that 
reperfusion rates tend to increase following 
sonopermeation (94±57% with 108 MBs; 47±9% with 
109 MBs; Figure 5B) and correlate with increasing 
drug uptake. The exact mechanism for improved 
perfusion rates (without changes in overall perfusion) 
in the Matrigel plugs following sonopermeation is 
unknown but may be attributed to pruning of the 
microvasculature and redirecting of blood to larger 
vessels more visible by ultrasound.  
One of the key findings from our Matrigel study 
was that low-intensity ultrasound was able to 
facilitate small molecule drug delivery to Matrigel 
plugs in vivo, but not liposomal drug carriers (Figure 
4C-D). We used high dosage chemotherapy (25 
mg/kg doxorubicin) to facilitate visualization and 
detection of accumulated doxorubicin in these 
studies, however no increase in doxorubicin uptake 
could be observed with increasing ultrasound 
intensity. We rationalized that the encapsulation of 
doxorubicin into liposomes, which increases the 
overall drug size to ~80nm, likely requires higher 
levels of permeabilization to effectively extravasate 
into tissue, although other factors such as doxorubicin 
low quantum efficiency may also have resulted in 
poor detection in Matrigel plugs. In order to improve 
delivery, we sought to increase the ultrasound 
intensity applied during sonopermeation. The 
maximum output of the therapeutic transducer was 
~0.6 MPa. To achieve higher ultrasound intensities, 
we developed an acrylic focusing lens that attached to 
the soundhead of the therapeutic ultrasound system 
(Supplementary Figure 1A). Using our focusing lens, 
we could apply higher amplitudes of pressure (up to 2 
MPa) at the focus to the Matrigel plugs while imaging 
concurrently with a clinical scanner. Utilizing 
ultrasound as a guide to position the focus, we were 
able to demonstrate significantly enhanced levels of 
liposome uptake in the Matrigel plugs, using 
fluorescence microscopy of liposomes in sections of 
Matrigel plugs (Figure 5C). At our maximum power 
setting and high dosage of bubbles (1x109 bubbles in 
500 µL), the highest level of liposome delivery was 
observed without significant change in total perfusion 
following sonopermeation therapy (Figure 5A). This 
enhancement in liposomal uptake with increasing 
microbubble concentration is believed to be a 
consequence of higher degrees of vascular 
permeabilization. In Matrigel plugs, injections of both 
109 and 108 MBs show increases in reperfusion rates 
(RR) after sonopermeation, however no significant 
difference between these two concentrations was 





observed. We attribute this to overall poor perfusion 
of Matrigel tumors which likely decreases sensitivity 
and increases variability in qCEUS imaging at lower 
MB concentrations. Since the change in RR was 
statistically significant at both microbubble 
concentrations, while no significant change in RBV 
was detected, we concluded that RR is a more 
sensitive measure of sonopermeation effect. It may be 
possible to improve accuracy using the area under the 
curve (AUC), which accounts for both RR and RBV 
terms in a single metric. This strategy has been used 
by similar groups [52] and will be pursued in future 
studies involving NGP tumors. 
We then demonstrated that efficient L-DOX 
delivery could be attained using our focused 
ultrasound system. Doxorubicin measurements were 
taken in excised Matrigel plugs, liver, contralateral 
kidney, and heart tissue. Our results disclosed nearly 
a 5-fold increase in doxorubicin uptake in Matrigel 
plugs using focused ultrasound mediated 
sonopermeation (Figure 6), with no change in uptake 
in the heart. Therefore, it stands to reason that lower 
dosages could be applied to reduce overall 
cardiotoxicity while simultaneously improving 
intratumoral drug uptake.  
Monitoring Sonopermeation and Evaluating 
Doxorubicin Uptake in Neuroblastoma Models  
Recognizing the limitations of the Matrigel plug 
model, the next phase of our project aimed to evaluate 
whether qCEUS imaging could effectively monitor 
sonopermeation in a highly relevant and 
well-characterized tumor model of human 
neuroblastoma. Similar to our previous results, TIC 
analysis illustrated that sonopermeated sections of NB 
tumors did not experience an overall decrease in their 
level of perfusion as compared to non-sonopermeated 
sections of tissue lying outside the tumor boundary 
(Figure 8A). This finding is inconsistent with the work 
of Burke et al [52] who reported significantly reduced 
perfusion following 60 min of sonopermeation 
therapy using an order of 106 MBs at four different 
low duty cycle US pulsing schemes. Rather than 
relying on a tethered or co-injected chemotherapeutic 
agent to bring about anti-tumor effects, this group 
activated the tumor apoptotic pathway by provoking 
microvascular damage using microbubble cavitation. 
They reasoned that mechanical ablation due to 
ultrasonic microbubble destruction leads to reduced 
blood flow, which in turn diminishes tissue 
oxygenation and nutrient delivery, ultimately 
inhibiting tumor growth and lowering the number of 
viable tumor cells.  
Identifying changes in tumor vasculature during 
sonopermeation is imperative, as blood vessels are the 
route of systemic chemotherapeutic delivery. Our 
results are particularly important as we can 
demonstrate that permeabilization of the vasculature 
is occurring without significant disruption of blood 
flow, which is crucial for increasing intratumoral drug 
penetration. We expect that increased levels of 
ultrasound exposure would eventually result in 
microvessel destruction or thermal ablation of tissue 
(which could also be measured by qCEUS imaging), 
but did not observe localized heating or tissue 
damage under the conditions we tested 
(Supplementary Figure 2). 
 Similar to earlier findings in Matrigel plug 
models, reperfusion kinetics of ultrasound contrast 
agents following flash destruction appeared to be a far 
more sensitive method of monitoring the effects of 
sonopermeation. However, contrary to our earlier 
findings, we observed a significant decrease in the 
rate of microbubble reperfusion (instead of increase) 
in sonopermeated tissue (Figure 8B, p<0.01) 
compared with unsonopermeated control tissue. This 
result, taken together with the evidence showing no 
change in relative blood volume of sonopermeated 
tumors (Figure 8A), indicates that vascular 
permeabilization was achieved without inducing 
blood vessel damage or destruction. We conjecture 
that the decrease in the rate of reperfusion is a direct 
result of increased hematocrit in the wholly intact 
blood vessels – that is, microbubble destruction 
effectively permeabilizes the vascular endothelium, 
causing plasma to leak out, thus raising viscosity 
within the lumen of the vessels. This in turn produces 
higher resistance to microbubble flow which is 
reflected in the qCEUS-derived time-intensity curve 
(TIC). To explore this phenomenon, we performed 
photoacoustic imaging to measure hemoglobin 
content within the tumor, before and after 
sonopermeation (Supplementary Figure 4). As 
hemoglobin is readily detectable and functions as an 
effective endogenous scatterer [53], hemoglobin was 
treated as a surrogate for hematocrit. Our preliminary 
results show an increase in hemoglobin content 
within the tumor immediately following 
sonopermeation, supporting the hypothesis that 
increases in hematocrit correlate with the observed 
increase in vascular permeability and improved drug 
uptake. Therefore, the biophysical effect that 
sonopermeation bears on microbubble perfusion 
kinetics – it appears to increase the fraction of red 
blood cells within vessels contained in the treated area 
– renders it an effective predictor of intratumoral drug 
uptake. No difference in oxygenated versus 
deoxygenated hemoglobin was observed. While this 
was only a single experiment, a recent report by 
Schultz et al [54] similarly demonstrated an increase in 





hemoglobin content in sonopermeated tumors using 
an analogous protocol, supporting our preliminary 
neuroblastoma data.  
To establish a link between drug uptake and 
sonopermeation kinetics in vivo, L-DOX 
accumulation, changes in tissue morphology, and 
apoptotic biomarkers were evaluated. As depicted in 
Figure 9B, sonopermeation resulted in a 2.3-fold 
increase in L-DOX uptake in NB xenografts as 
compared to mice that were infused with 
microbubbles and L-DOX without focused 
ultrasound, and a 4.8-fold increase in uptake 
compared with untreated controls (Figure 9B). A 
decrease in the density of blood vessels was not 
observed in the sonopermeation group, ascertained 
by lectin staining (Figure 9A, middle row). This 
constitutes a critical finding as sonopermeation is 
intended to drive increased concentrations of drug 
into the tumor without triggering vascular collapse. 
Since therapeutic agents utilize the vasculature as a 
physical route to reach their target site, inflicting 
irreversible damage on the vasculature (endothelium 
and/or pericytes) would be detrimental to the goal of 
depositing large drug payloads into the tumor space, 
especially if repeated deliveries are to be attempted as 
required by most chemotherapy regimens. With this 
objective in mind, longitudinal studies investigating 
whether vascular changes associated with 
sonopermeation result in long-term remodeling 
(beyond 24 h) are still needed. In this particular body 
of work, we elected to only perform qCEUS during or 
immediately after sonopermeation and to evaluate 
changes in vasculature at 30 min and 24 h using ex 
vivo analysis; however, qCEUS imaging at extended 
time points in subsequent studies would more fully 
expound the tumor response to the increased 
doxorubicin payload.  
We also sought to determine whether 
ultrasound-triggered microbubble destruction 
induces apoptosis by itself, that is, in the absence of 
L-DOX. H&E stained sections of sonopermeated 
tumors exhibited no changes in architecture or 
apoptosis (Figure 8F) immediately following 
sonopermeation, but immunostaining of the pericyte 
marker αSMA did reveal discontinuous coverage of 
pericytes encircling the vascular endothelium (Figure 
8E). These changes in pericyte morphology suggest a 
mechanism for increased vascular permeability: 
loosening of interendothelial junctions, allowing 
greater extravasation. Future studies will address the 
longevity of these effects and explicate whether or not 
tight junctions are restored within 24 h. 
Broader Applications in a Clinical Setting 
While the focus of this study was on 
neuroblastoma, we believe that the techniques 
outlined can have broader applications in a clinical 
setting for perfusion-guided drug therapies in a wide 
range of cancers. Here, we present a single case study 
from an ongoing clinical trial where sonopermeation 
was performed using simultaneous imaging and 
therapy with a protocol resembling that described in 
this paper. The procedure for sonopermeation can be 
found in the methods section and is summarized in 
Figure 10A, along with quantitative flash-destruction 
imaging (Figure 10B) and results (Figure 10C). It is 
important to note some of the key differences, which 
include microbubble concentration, microbubble type, 
and ultrasound application, due to stringent FDA 
regulations. Despite barriers in comparing directly 
between animal and human testing, this data serves 
as proof-of-principle that the strategy used in this 
paper can have direct clinical impact.  
There are several challenges that still need to be 
overcome for human testing, including 
implementation of 3D imaging with motion correction 
to reduce variability in qCEUS imaging, and analysis 
of linearized data instead of logarithmically 
compressed video images. Importantly, real-time 
feedback to quantify reperfusion rates on-the-fly 
would be highly beneficial for evaluating 
sonopermeation efficiency during treatment. 
Additionally, more work needs to be done to correlate 
the qCEUS imaging parameters with long-term tumor 
response to therapy and overall survival. 
Conclusion 
Quantitative contrast-enhanced imaging is 
attracting increasing interest, as UCAs are being 
employed for both diagnostic imaging as well as 
therapy. The applications of qCEUS imaging have the 
unique and inherent capacity to offer real-time 
assessment of therapeutic effectiveness. Monitoring 
tissue permeability of a drug, as well as controlling 
drug uptake with qCEUS, may dramatically improve 
the clinical outcomes of therapeutic interventions. As 
utilization of qCEUS imaging continues to advance in 
clinical settings, the techniques proposed here could 
become increasingly valuable, leveraging the growing 
variety of nanoparticle drug therapies aimed at 
varying tumor types in combination with emerging 
ultrasound imaging technologies. 
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